▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3303 by analyst upside · 2026-11-13
USPH
U.S. Physical Therapy, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+11.1%
implied upside to consensus target
Current Price $98.6
Consensus Target $109.5
Bull Target $120.0
Bear Target $95.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
2
Hold
1
Sell
0
52-Week Low $58.19
52-Week High $101.37
YTD Return +27.4%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E 29.5x
EPS (TTM) $-1.33
PEG Ratio 3.28
Dividend Yield 1.87%
Revenue (TTM) $830M
Profit Margin 3.6%
52-WEEK RANGE
52-Week Low $58.19
52-Week High $101.37
Current Price $98.6
Bear Target $95.0
Bull Target $120.0
● Now $98.6 ● Target $109.5
TRADING DATA
Avg Volume 181K
YTD Return +27.4%
Analyst Count 6
Consensus Buy
Upside to Target +11.1%
Last Updated 2026-11-13

ANALYST SUMMARY

U.S. Physical Therapy, Inc. (USPH) is currently trading at $98.6 with a Wall Street consensus price target of $109.5, implying potential upside of 11.1% over the next 12 months. 6 analysts currently cover USPH, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $120.0, while the most cautious has a target of $95.0.

USPH operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 27.4% year-to-date and is currently trading near the upper end of its 52-week range of $58.19 – $101.37.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INVA +83.4%
Innoviva, Inc.
$1B · P/E 8.1x · Buy
UFPT +16.9%
UFP Technologies, Inc.
$2B · P/E 31.2x · Underperform
LMAT +27.9%
LeMaitre Vascular, Inc.
$2B · P/E 28.2x · Buy
HSTM +27.3%
HealthStream, Inc.
$866M · P/E 40.4x · Underperform
CNMD -7.2%
CONMED Corporation
$2B · P/E 20.9x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for USPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-09-11 43% win rate (7 calls)
Barrington Research - Reiterated
Outperform → Outperform 2026-08-10 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-06-24 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-05-13 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-02-20 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-01-05 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2025-11-24 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
15/30
Consensus clarity
25/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →